3-Ethoxycarbonyl-6,7-difluoroquinoxalin-2(1H)-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-Ethoxycarbonyl-6,7-difluoroquinoxalin-2(1H)-one
• 英文别名: ethyl 6,7-difluoro-3-hydroxyquinoxaline-2-carboxylate；ethyl 6,7-difluoro-3-oxo-4H-quinoxaline-2-carboxylate
• 化学式: C₁₁H₈F₂N₂O₃
• 分子量: 254.193
• InChiKey: OQIPQIAPBBVFDP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-Ethoxycarbonyl-6,7-difluoroquinoxalin-2(1H)-one 在 三氯氧磷 作用下， 反应 5.0h， 以84%的产率得到2-Chloro-6,7-difluoro-3-ethoxycarbonylquinoxaline
  参考文献：
  名称：

  Quinoxaline chemistry. Part 13: 3-carboxy-2-benzylamino-substituted quinoxalines and N-[4-[(3-carboxyquinoxalin-2-yl) aminomethyl]benzoyl]-l-glutamates: synthesis and evaluation of in vitro anticancer activity

  摘要：

  Among a new series of 28 3-carboxy or carbethoxy quinoxalines bearing a substituted benzylamino or N-[4-(aminomethyl)benzoyl]glutamate group on position 2 of the ring and various substituents at C-6, 7 positions, 21 were selected at the National Cancer Institute for evaluation of their in vitro anticancer activity. The results obtained seem to confirm that the carboxy or carbethoxy group on position 3 is not helpful, with a few exceptions, for the anticancer activity. (C) 2000 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0014-827x(99)00119-6
• 作为产物：
  描述：

  4,5-二氟-2-硝基苯胺 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 3-Ethoxycarbonyl-6,7-difluoroquinoxalin-2(1H)-one
  参考文献：
  名称：

  Synthesis of substituted 2-ethoxycarbonyl- and 2-carboxyquinoxalin-3-ones for evaluation of antimicrobial and anticancer activity

  摘要：

  A series of variously substituted quinoxalin-3-ones bearing an ethoxycarbonyl or carboxy group in the C-2 position has been prepared and their structures proved by H-1 NMR spectroscopy. The obtained compounds were investigated in vitro for antimicrobial and anticancer activities. Preliminary results showed a moderate activity against a few strains of bacteria but no significant anticancer and anti-HIV activity. (C) 1998 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0014-827x(98)00044-5
• 作为试剂：
  描述：

  4,5-二氟-2-硝基苯胺 、 氢气 、 酮基丙二酸二乙酯 在 钯 4,5-二氟苯-1,2-二胺 、 3-Ethoxycarbonyl-6,7-difluoroquinoxalin-2(1H)-one 作用下， 以 乙醇 为溶剂， 生成 3-Ethoxycarbonyl-6,7-difluoroquinoxalin-2(1H)-one
  参考文献：
  名称：

  Treatment of influenza with

  摘要：

  3,4-二氢-3-氧代喹啉在2号位带有羧酸或酯基团，可用作抗病毒剂，特别是对甲型和乙型流感病毒有效。

  公开号：

  US04264600A1

文献信息

• Treatment of influenza with
  申请人：Eli Lilly and Company

  公开号：US04264600A1

  公开（公告）日：1981-04-28

  3,4-Dihydro-3-oxoquinoxalines carrying a carboxylic acid or ester function in the 2 position, used as antiviral agents, particularly against influenza virus, both A and B strains.

  3,4-二氢-3-氧喹啉在2位携带羧酸或酯基团，用作抗病毒剂，特别是对抗流感病毒，包括A和B型。
• [EN] AMINO-QUINOXALINE AND AMINO-QUINOLINE COMPOUNDS FOR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS<br/>[FR] AMINO-QUINOXALINE ET COMPOSÉS AMINO-QUINOLINE À UTILISER EN TANT QU'ANTAGONISTES DU RÉCEPTEUR A2a
  申请人：SCHERING CORP

  公开号：WO2009111442A1

  公开（公告）日：2009-09-11

  Compounds of the Formula (I), where W represents CH or N; and Q represents -CN, -C(=NOH)NH2, -CONHR1 or various herein described heterocyclic radicals; as well as pharmaceutically acceptable salts, solvates, esters and prodrugs thereof are adenosine A2a receptor antagonists and, therefore, are useful in the treatment of central nervous system diseases, in particular Parkinson's disease.

  化合物的分子式（I），其中W代表CH或N；Q代表-CN，-C（=NOH）NH2，-CONHR1或这里描述的各种杂环基团；以及其药学上可接受的盐类、溶剂化合物、酯类和前药是腺苷A2a受体拮抗剂，因此在治疗中枢神经系统疾病，特别是帕金森病方面具有用处。
• INHIBITORS OF FATTY ACID BINDING PROTEIN
  申请人：CHENG CLIFFORD

  公开号：US20120122837A1

  公开（公告）日：2012-05-17

  The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

  本发明涉及一种新颖的杂环化合物，作为脂肪酸结合蛋白（“FABP”）抑制剂，包括含有这些杂环化合物的药物组合物，并且利用这些化合物用于治疗或预防心血管疾病、代谢紊乱、肥胖或与肥胖相关的疾病、糖尿病、血脂异常、糖尿病并发症、糖耐量受损或空腹血糖受损。
• AMINO-QUINOXALINE AND AMINO-QUINOLINE COMPOUNDS FOR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
  申请人：Harris Joel M.

  公开号：US20110105513A1

  公开（公告）日：2011-05-05

  Compounds of the Formula (I), where W represents CH or N; and Q represents —CN, —C(═NOH)NH 2 , —CONHR 1 or various herein described heterocyclic radicals; as well as pharmaceutically acceptable salts, solvates, esters and prodrugs thereof. Care adenosine A 2a receptor antagonists and, therefore, are useful in the treatment of central nervous system diseases, in particular Parkinson's disease.

  化合物的公式（I），其中W代表CH或N; Q代表—CN、—C(═NOH)NH2、—CONHR1或各种在此描述的杂环基团; 以及其药学上可接受的盐、溶剂化物、酯和前药。这些化合物是腺苷A2A受体拮抗剂，因此在中枢神经系统疾病，特别是帕金森病的治疗中是有用的。
• Substituted quinoxalines as inhibitors of fatty acid binding protein
  申请人：Cheng Clifford

  公开号：US08889683B2

  公开（公告）日：2014-11-18

  The present invention relates to novel quinoxaline compounds of Formula I: as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the quinoxaline compounds and the use of the quinoxaline compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

  本发明涉及一种新型喹喔啉化合物，化学式为I：作为脂肪酸结合蛋白（“FABP”）抑制剂，包含该喹喔啉化合物的药物组合物以及使用该喹喔啉化合物治疗或预防心血管疾病、代谢紊乱、肥胖或肥胖相关疾病、糖尿病、血脂异常、糖尿病并发症、糖耐量受损或空腹血糖受损的用途。